Patients with atypical Hemolytic-Uremic Syndrome will be asked to participate in this study.  Atypical Hemolytic-Uremic Syndrome(aHUS) is a rare, chronic, immune system disorder that causes abnormal blood clotting and inflammation, that can lead to damage to the body’s vital organs, such as the kidneys, heart and brain.

This Registry study will collect safety and effectiveness information about the treatments used to treat it, including the use of the infusion drug, eculizumab.  We will also collect data on the long term outcome of the disease itself.  This Registry research study is enrolling patients from many hospitals around the world and will enroll an unlimited number of patients.

aHUS Registry Study

M11-001: An Observational, Non-Interventional, Multicenter, Multinational Study of Patients with Atypical Hemolytic-Uremic Syndrome

Principal Investigator

Andrew Siedlecki, MD